The TechMediaWire Podcast

BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safety to healthcare and public health management. Traditional methods such as breathalyzers, blood tests and urine screenings are often limited by their invasiveness, delayed results or inability to assess real-time impairment, particularly in cases involving multiple substances. As patterns of substance use evolve and the societal costs of impaired behavior continue to rise, the demand for faster, more scalable and noninvasive diagnostic solutions is becoming increasingly urgent. MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) (Profile) is advancing a novel approach that leverages artificial intelligence (“AI”) and voice analysis to predict intoxication from short speech samples. By focusing on the human voice as a measurable indicator of internal physiological and cognitive states, the company is working to develop a platform capable of detecting impairment across a range of substances in real-time. This approach not only addresses a critical gap in existing detection methods but also reflects a broader shift toward AI-driven, noninvasive diagnostics with the potential to transform regulatory enforcement, workplace safety and public health outcomes. MindBio joins other key companies operating at the forefront of health, AI and diagnostics technologies, including HeartFlow Inc. (NASDAQ: HTFL), Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), Tempus AI Inc. (NASDAQ: TEM) and Butterfly Network Inc. (NYSE: BFLY).

• The global impact of drug and alcohol use presents significant public health and safety challenges.
• MindBio Therapeutics is establishing a unique position in the emerging field of voice-based diagnostics by combining artificial intelligence with speech analysis to detect intoxication.
• MindBio is targeting a total addressable market of approximately $47 billion in workplace safety and substance testing, driven by regulatory requirements across industries as varied as mining, aviation, construction and transportation.
• One of the most compelling aspects of MindBio Therapeutics’ technology is its ability to detect multiple substances through analysis of speech patterns.
• As adoption of AI-driven diagnostics continues to expand, innovations in this space, including MindBio’s voice-based platform, could play a pivotal role in shaping the future of public safety and healthcare.

For further information about MindBio Therapeutics Corp., visit the MindBio Therapeutics profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com